Hepion Pharmaceuticals, Inc.
HEPA
$0.08
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.12M | 7.50M | 7.48M | 7.93M | 8.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.44M | 19.35M | 25.36M | 31.57M | 37.23M |
| Operating Income | -15.44M | -19.35M | -25.36M | -31.57M | -37.23M |
| Income Before Tax | -16.44M | -16.16M | -26.08M | -31.74M | -41.90M |
| Income Tax Expenses | 0.00 | -2.97M | -3.38M | -3.38M | -3.38M |
| Earnings from Continuing Operations | -16.44 | -13.19 | -22.70 | -28.37 | -38.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.44M | -13.19M | -22.70M | -28.37M | -38.52M |
| EBIT | -15.44M | -19.35M | -25.36M | -31.57M | -37.23M |
| EBITDA | -15.44M | -19.32M | -25.32M | -31.51M | -37.15M |
| EPS Basic | -83.31 | -109.29 | -223.67 | -324.59 | -474.72 |
| Normalized Basic EPS | -80.54 | -128.02 | -167.48 | -231.38 | -301.53 |
| EPS Diluted | -83.31 | -109.29 | -223.67 | -324.59 | -474.72 |
| Normalized Diluted EPS | -80.54 | -128.02 | -167.48 | -231.38 | -301.53 |
| Average Basic Shares Outstanding | 3.23M | 491.20K | 440.00K | 382.40K | 342.90K |
| Average Diluted Shares Outstanding | 3.23M | 491.20K | 440.00K | 382.40K | 342.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |